Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients
NCT ID: NCT02813642
Last Updated: 2022-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
400 participants
INTERVENTIONAL
2011-12-08
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis
NCT04810338
Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients
NCT01327391
Assessment of Professional Practices in Muscle Rehabilitation of Chronic Hemodialysis
NCT04820140
Intradialytic Exercise and Remote Ischaemic Preconditioning: a Cardioprotective Role ?
NCT06856512
The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.
NCT03942744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiovascular risk evaluation
Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Vascular calcification score
measurement of vascular calcification score by X-ray of the lateral abdominal aorta
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Vascular calcification score
measurement of vascular calcification score by X-ray of the lateral abdominal aorta
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with chronic renal failure starting dialysis therapy
Exclusion Criteria
* Patient with chronic renal failure not yet on dialysis therapy
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Paul Cristol, Prof
Role: PRINCIPAL_INVESTIGATOR
CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hémodialyse du Lez
Castelnau-le-Lez, , France
AIDER
Montpellier, , France
CHU Montpellier, Nephrology department
Montpellier, , France
CH Nimes, Nephrology department
Nîmes, , France
CH Perpignan, Nephrology department
Perpignan, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sébastien Deleuze, Dr
Role: primary
Lotfi Chalabi, Dr
Role: primary
Hélène Leray-Moragues, Dr
Role: primary
Pascal Reboul, Dr
Role: primary
Carlos Vela, Dr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UF8851
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.